Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies

Biochemical and Biophysical Research Communications

Volumn 407, Issue 2, 2011, Pages 412-419

  Oliveras Ferraros, Cristina ^a,b   Vazquez Martin, Alejandro ^a,b   Cufí, Sílvia ^a,b   Torres Garcia, Violeta Zenobia ^a,b   Sauri Nadal, Tamara ^a,b   Barco, Sonia Del ^a,b   Lopez Bonet, Eugeni ^b,c   Brunet, Joan ^a,b   Martin Castillo, Begoña ^a,b   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Breast cancer; HER2; Lapatinib; Survivin; Trastuzumab

Indexed keywords

DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; INHIBITOR OF APOPTOSIS PROTEIN; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; SURVIVIN; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IC 50; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA INTERFERENCE;

EID: 79953725183     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.039     Document Type: Article

References (26)

1. Oliveras-Ferraros C., Vazquez-Martin A., Martin-Castillo B., et al. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem. Biophys. Res. Commun. 2010, 397:27-33.
2. Tanner M., Kapanen A.I., Junttila T., et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol. Cancer Ther. 2004, 3:1585-1592.
3. G. Valabrega, S. Capellero, G. Cavalloni, et al., HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib, Breast Cancer Res. Treat. 2010 Dec 9 [Epub ahead of print].
4. Nagy P., Friedländer E., Tanner M., et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005, 65:473-482.
5. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
6. Chen K.F., Tai W.T., Liu T.H., et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 2010, 16:5189-5199.
7. Zhu H., Zhang G., Wang Y., et al. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. Cancer Sci. 2010, 101:1156-1162.
8. Chen F.L., Xia W., Spector N.L. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin. Cancer Res. 2008, 114:6730-6734.
9. Menendez J.A., Vazquez-Martin A., Colomer R., et al. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer 2007, 7:80.
10. Vazquez-Martin A., Colomer R., Brunet J., Menendez J.A. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int. J. Oncol. 2007, 31:769-776.
11. Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 2009, 4:e6251.
12. A. Vazquez-Martin, C. Oliveras-Ferraros, S.D. Barco, et al., The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells, Breast Cancer Res. Treat. 2010 May 11 [Epub ahead of print].
13. Vazquez-Martin A., Oliveras-Ferraros C., Colomer R., et al. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann. Oncol. 2008, 19:1097-1109.
14. Vázquez-Martín A., Oliveras-Ferraros C., del Barco S., et al. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin. Transl. Oncol. 2009, 11:455-459.
15. Konecny G.E., Pegram M.D., Venkatesan N., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66:1630-1639.
16. Nahta R., Yuan L.X., Du Y., Esteva F.J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol. Cancer Ther. 2007, 6:667-674.
17. Vazquez-Martin A., Oliveras-Ferraros C., del Barco S., et al. The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors cardiomyopathy. Ann. Oncol. 2009, 20:592-595.
18. Oliveras-Ferraros C., Vazquez-Martin A., Martin-Castillo B., et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int. J. Oncol. 2010, 37:669-678.
19. Xia W., Gerard C.M., Liu L., et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005, 24:6213-6221.
20. Asanuma H., Torigoe T., Kamiguchi K., et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005, 65:11018-11025.
21. Xia W., Bisi J., Strum J., et al. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 2006, 66:1640-1647.
22. Xia W., Bacus S., Hegde P., et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA 2006, 103:7795-7800.
23. Foster F.M., Owens T.W., Tanianis-Hughes J., et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res. 2009, 11:R41.
24. Ryan B.M., Konecny G.E., Kahlert S., et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann. Oncol. 2006, 17:597-604.
25. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35:553-562.
26. Kanwar R.K., Cheung C.H., Chang J.Y., Kanwar J.R. Recent advances in anti-survivin treatments for cancer. Curr. Med. Chem. 2010, 17:1509-1515.